减低强度预处理联合更换供者二次异基因造血干细胞移植治疗首次移植后复发的恶性血液病
该回顾性研究纳入44例首次异基因造血干细胞移植后复发的恶性血液病患者,采用减低强度预处理、全部更换供者行二次移植。中位随访14个月,1年无病生存率72.5%、总生存率80.6%、累积复发率25.1%,非复发死亡率2.3%;二次移植前完全缓解者1年累积复发率显著低于未缓解者(16.8% vs 48.1%,P=0.026)。
要点
- 全部患者更换供者行二次移植,1年总生存率80.6%、无病生存率72.5%、非复发死亡率2.3%。
- 二次移植前完全缓解者1年累积复发率16.8%,显著低于未缓解者的48.1%(P=0.026)。
- 二次移植前原发病是否完全缓解是影响预后的因素。
核心结论
- 采用减低强度预处理方案、更换供者及移植后维持治疗等策略的二次异基因造血干细胞移植治疗首次移植后复发的恶性血液病具有较好的安全性及疗效。
- 影响二次移植预后的最重要因素是二次移植前的疾病状态。
研究设计与样本
- 回顾性分析2018年4月至2021年6月于北京高博博仁医院造血干细胞移植科接受减低强度预处理、更换供者二次移植的44例移植后复发恶性血液病患者。
- 病种构成:急性B淋巴细胞白血病23例、急性T淋巴细胞白血病/T淋巴母细胞性淋巴瘤4例、急性髓系白血病15例、骨髓增生异常综合征2例。
- 首次移植供者类型为无关供者12例、单倍体供者32例,所有患者二次移植时均更换供者。
- 预处理方案:全身放射治疗/氟达拉滨38例、白消安/氟达拉滨4例、全骨髓照射/氟达拉滨1例、白消安/克拉屈滨1例。
- 移植物抗宿主病预防采用环孢素A、霉酚酸酯、短程甲氨蝶呤及抗胸腺细胞球蛋白。
主要发现
- 中位年龄25(7~55)岁,两次移植间隔中位时间19.5(6~77)个月,二次移植前完全缓解33例(75.0%)、未缓解11例(25.0%)。
- 所有患者均获得造血重建,Ⅱ~Ⅳ度、Ⅲ~Ⅳ度急性移植物抗宿主病发生率分别为20.5%、9.1%,局限型、广泛型慢性移植物抗宿主病发生率分别为20.5%、22.7%。
- 巨细胞病毒、EB病毒感染发生率分别为29.5%、6.8%,出血性膀胱炎发生率为15.9%(均为Ⅰ~Ⅱ度)。
- 中位随访14(2~39)个月,1年无病生存率72.5%(95% CI 54.5%~84.3%)、总生存率80.6%(95% CI 63.4%~90.3%)、累积复发率25.1%(95% CI 13.7%~43.2%)。
- 8例死亡(7例死于复发、1例死于感染),非复发死亡率2.3%;完全缓解组与未缓解组1年累积复发率分别为16.8%、48.1%(P=0.026),1年无病生存率分别为79.9%、51.9%(P=0.072)。
关键数值与推荐
- 二次移植前完全缓解组1年累积复发率16.8% vs 未缓解组48.1%(P=0.026)。
- 二次移植前完全缓解组1年无病生存率79.9% vs 未缓解组51.9%(P=0.072),差异无统计学意义。
- 单因素分析显示二次移植前原发病是否完全缓解是预后的影响因素。
临床怎么用
- 作者认为,采用减低强度预处理方案、更换供者及移植后维持治疗的二次异基因造血干细胞移植是首次移植后复发恶性血液病安全有效的治疗。
- 作者认为,影响二次移植预后的最重要因素是二次移植前的疾病状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The purpose of this study was to assess the safety and efficacy of a second allogeneic hematopoietic stem cell transplantation (allo-HSCT) with reduced-intensity conditioning (RIC) in patients with hematological malignancies who had relapsed after the first allo-HSCT. Methods: Between April 2018 and June 2021, 44 patients with hematological malignancies (B-ALL 23, T-ALL/T-LBL 4, AML15, and MDS 2) were enrolled and retrospectively examined. Unrelated donors (n=12) or haploidentical donors (n=32) were used. Donors were replaced in all patients for the second allo-HSCT. Hematological and immunological germline predisposition genes and hematopoietic and immune function tests were used to select the best-related donor. Total body irradiation (TBI) /fludarabine (FLU) -based (n=38), busulfan (BU) /FLU-based (n=4), total marrow irradiation (TMI) /FLU-based (n=1), and BU/cladribine-based (n=1) were the RIC regimens used. For graft versus host disease (GVHD) prevention, cyclosporine, mycophenolate mofetil, short-term methotrexate, and ATG were used. Eighteen (40.9%) of 44 patients with gene variations for which targeted medications are available underwent post-transplant maintenance therapy. Results: The median age was 25 years old (range: 7-55). The median interval between the first and second HSCT was 19.5 months (range: 6-77). Before the second allo-HSCT, 33 (75%) of the patients were in complete remission (CR), whereas 11 (25%) were not. All patients had long-term engraftment. The grade Ⅱ-Ⅳ GVHD and severe acute GVHD rates were 20.5% and 9.1%, respectively. Chronic GVHD was found in 20.5% of limited patterns and 22.7% of severe patterns. CMV and EBV reactivation rates were 29.5% and 6.8%, respectively. Hemorrhage cystitis occurred in 15.9% of cases, grade Ⅰ or Ⅱ. The 1-yr disease-free survival (DFS), overall survival (OS), and cumulative recurrence incidence (RI) rates of all patients were 72.5% (95% CI, 54.5%-84.3%), 80.6% (95% CI, 63.4%-90.3%), and 25.1% (95% CI, 13.7%-43.2%), respectively, with a median follow-up of 14 (2-39) months. There were eight deaths (seven relapses and one infection). The rate of non-relapse mortality (NRM) was only 2.3%. The CR patients' 1-yr RI rate was significantly lower than the NR patients (16.8% vs 48.1%, P=0.026). The DFS rate in CR patients was greater than in NR patients, although there was no statistical difference (79.9% vs 51.9%, P=0.072). Univariate analysis revealed that CR before the second allo-HSCT was an important prognostic factor. Conclusion: With our RIC regimens, donor change, and post-transplant maintenance therapy, the second allo-HSCT in relapsed hematological malignancies after the first allo-HSCT is a safe and effective treatment with high OS and DFS and low NRM and relapse rate. The most important factor influencing the prognosis of the second allo-HSCT is the patient's illness condition before the transplant. 目的: 评估减低强度预处理(RIC)、更换供者二次异基因造血干细胞移植(二次移植)治疗移植后复发恶性血液病的疗效及安全性。 方法: 纳入2018年4月至2021年6月于北京高博博仁医院造血干细胞移植科接受RIC、更换供者二次移植的44例移植后复发恶性血液病患者,回顾性分析其临床资料。 结果: ①全部44例患者中男21例,女23例,中位年龄25(7~55)岁;急性B淋巴细胞白血病23例,急性T淋巴细胞白血病/T淋巴母细胞性淋巴瘤4例,急性髓系白血病15例,骨髓增生异常综合征2例;首次allo-HSCT供者类型包括无关供者12例、单倍体供者32例,所有患者在二次移植时均更换了供者;两次allo-HSCT间隔的中位时间为19.5(6~77)个月;二次移植前33例(75.0%)患者原发病为完全缓解,11例(25.0%)为未缓解;预处理方案包括全身放射治疗/氟达拉滨(38例)、白消安/氟达拉滨(4例)、全骨髓照射/氟达拉滨(1例)、白消安/克拉屈滨(1例);采用环孢素A、霉酚酸酯、短程甲氨蝶呤及抗胸腺细胞球蛋白预防移植物抗宿主病(GVHD)。②所有患者均获得造血重建,Ⅱ~Ⅳ度、Ⅲ~Ⅳ度急性GVHD发生率分别为20.5%、9.1%,局限型、广泛型慢性GVHD发生率分别为20.5%、22.7%,巨细胞病毒、EB病毒感染发生率分别为29.5%、6.8%,出血性膀胱炎发生率为15.9%(均为Ⅰ~Ⅱ度)。③中位随访14(2~39)个月,移植后1年无病生存率、总生存率分别为72.5%(95% CI 54.5%~84.3%)、80.6%(95% CI 63.4%~90.3%),累积复发率为25.1%(95% CI 13.7%~43.2%)。8例患者死亡,7例死于复发,1例死于感染,非复发死亡率为2.3%。④二次移植前完全缓解组、未缓解组移植后1年累积复发率分别为16.8%、48.1%(P=0.026),无病生存率分别为79.9%、51.9%(P=0.072)。⑤单因素分析显示二次移植前原发病是否完全缓解是预后的影响因素。 结论: 采用RIC方案、更换供者及移植后维持治疗等策略的二次移植治疗allo-HSCT后复发的恶性血液病具有较好的安全性及疗效。影响二次移植预后的最重要因素是二次移植前的疾病状态。.
引用
- Zhao YQ, Song YZ, Li ZH, et al. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37550201. doi:10.3760/cma.j.issn.0253-2727.2023.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。